EUnetHTA Magazine – Winter 2021 – now available

We are please to finally publish another issue of the EUnetHTA Magazine, a collection of articles submitted by members and stakeholders that deal with HTA in Europe, EUnetHTA tasks and output, and, of course, COVID-19 and the network’s reprioritization this year towards it. We normally try to publish quarterly. However, 2020 has proven to be […]

EUnetHTA – Open Letter of Comment

This is an open letter, written by the Chair of the EUnetHTA Executive Board, Niklas Hedberg. It expresses commentary on the role of EUnetHTA within European HTA, and that of scientific journals. Please access the letter here: EUnetHTA – Open Letter of Comment For any questions regarding this, please contact the EUnetHTA Secretariat team at eunethta@zinl.nl

Minutes of EMA/EUnetHTA virtual meeting

We are pleased to publish the minutes of the 13 July 2020 meeting held between the European Medicines Agency (EMA) and EUnetHTA. The meeting covered updates on EMA/EUnetHTA collaboration, JA3 final phase priorities, and 201-2021 Work Plan review, in addition to COVID-19 publication focus and other topics. Please access at this link: EMA-EUnetHTA July 2020 […]

EMA-EUnetHTA Bilateral Meeting July 2020 – minutes now available

We are pleased to publish the minutes of the 13 July 2020 meeting held between the European Medicines Agency (EMA) and EUnetHTA. The meeting covered updates on EMA/EUnetHTA collaboration, JA3 final phase priorities, and 201-2021 Work Plan review, in addition to COVID-19 publication focus and other topics. Please access at this link: EMA-EUnetHTA July 2020 […]

RCROT02 – Rapid Collaborative Review on the diagnostic accuracy of molecular methods that detect the presence of SARS-CoV-2 virus in people with suspected COVID-19 – report now available

EUnetHTA is pleased to announce that the “Rapid Collaborative Review on the diagnostic accuracy of molecular methods that detect the presence of SARS-CoV-2 virus in people with suspected COVID-19” is now available. This is the second rapid review assessing health technologies for SARS-CoV-2. The objective of this assessment was to identify, assess and summarise evidence on […]

OTCA28 – ‘Lung cancer screening in risk groups’ – final assessment now available

We are pleased to announce that the collaborative assessment, OTCA28 – ‘Lung cancer screening in risk groups’ – is now available. The aim of this EUnetHTA Assessment is to provide a reliable synthesis and analysis of the available evidence on lung cancer screening in risk groups (persons with history of smoking or current smokers, persons […]

PTJA10 – Crizanlizumab for the prevention of vaso-occlusive crises in sickle cell disease patients aged 16 years and older – Final assessment now available

This is the pharmaceutical Joint Assessment PTJA10 – Crizanlizumab for the prevention of vaso-occlusive crises in sickle cell disease patients aged 16 years and older. In October, 2020, the European Commission granted conditional marketing authorisation for Adakveo® (crizanlizumab) for the prevention of vaso-occlusive crises in sickle cell disease patients aged 16 years and older. Publication of […]

OTCA25 Final Project Plan and related documents now available

The Final Project Plan and comments from external experts are now available for the Other Technologies Collaborative Assessment 25 (OTCA25) ‘Stereotactic Body Radiation Therapy (SBRT) for lung, prostate and liver cancer’. Please access at the following links: OTCA25 Final Project Plan OTCA25 Comments from External Experts

PTRCR18 – Dexamethasone for the treatment of hospitalised patients with COVID-19 – Final Rapid Collaborative Review now available.

This is the second pharmaceutical Rapid Collaborative Review (PTRCR18) published by EUnetHTA. This report describes dexamethasone for the treatment of COVID-19 patients. In September, 2020, the European Commission endorsed the use of dexamethasone for the treatment of COVID-19 patients on oxygen or mechanical venilation. This Rapid Collaborative Review aims to define, according to the national […]

PTRCR15 – remdesivir for the treatment of COVID-19. First update, December 2020.

In June, 2020, the European Commission granted marketing authorisation for Veklury® (remdesivir) for the treatment of Covid-19. This is the first update on the pharmaceutical Rapid Collaborative Review (PTRCR15) for – Remdesivir for the treatment of COVID-19. Following the original Rapid Collaborative Review – PTRCR15, published in September 2020, evidence gaps were identified, such as the […]